AstraZeneca
2025.06.15
11:42
AstraZeneca's global oncology business Dato-DXd and lung cancer business unit head Lai Minglong has decided to leave
Reporters learned that Lai Minglong, head of AstraZeneca's global oncology business Dato-DXd and lung cancer business unit, has decided to resign and seek external development opportunities. His last working day will be June 30. AstraZeneca told reporters that the news is true. Public information shows that Lai Minglong joined AstraZeneca in June 2017 and became vice president of AstraZeneca's cardiovascular and metabolic business unit in China. He was promoted to general manager of AstraZeneca China in 2018.
2025.06.13
08:56
CSPC Pharmaceutical Group and AstraZeneca reach a licensing cooperation of more than US$5 billion
On June 13, AstraZeneca announced a strategic research collaboration with CSPC Pharmaceutical Group. According to the agreement, AstraZeneca and CSPC Pharmaceutical Group agreed to discover and develop preclinical drug candidates with potential for treating multiple chronic diseases for multiple targets, including a preclinical small molecule oral therapy for immune diseases. CSPC Pharmaceutical Group will receive an advance payment of US$110 million and is eligible for potential R&D milestone payments of up to US$1.62 billion and potential sales milestone payments of up to US$3.6 billion, as well as potential single-digit sales commissions based on the annual net sales of the relevant products. From this point of view, through licensing cooperation, CSPC Pharmaceutical Group is expected to receive more than US$5 billion.
2025.06.04
09:00
AstraZeneca's Invitrogen approved in China
On June 4, AstraZeneca announced that Imfinzi (generic name: Durvalumab) has been approved by the China National Medical Products Administration (NMPA) as a single agent for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) who have not experienced disease progression after platinum-based chemoradiotherapy.
2025.05.20
16:18
AstraZeneca's AirSupra reduces asthma exacerbation risk by 47%, study shows
AstraZeneca's AirSupra can reduce the risk of acute asthma attacks by 47%, research shows.
2025.05.16
07:47
The “Yangtze River Delta AI Biomedicine Industry Alliance” was officially established
On May 16, the 2025 Taihu Bay Life and Health Future Conference with the theme of "Digital Intelligence Empowers Health and Starts the Future" was held in Wuxi. AstraZeneca, Wuxi High-tech Zone, and the Yangtze River Delta Health Research Institute of Ruijin Hospital jointly launched the "Ruijin Yangtze River Delta Metabolic Industry Park". In addition, the "Yangtze River Delta AI Biomedicine Industry Alliance" jointly initiated by AstraZeneca, Peking University Yangtze River Delta Future Technology Life and Health Research Institute, Insilicon Valley Medicine, and Shanghai Yangtze River Delta Medical Innovation Life and Health Industry Foundation and other leading industry-university-research institutions was also officially established.
2025.05.12
08:12
U.S. pharmaceutical stocks fell before the market opened, with Novo Nordisk, AbbVie and others leading the decline
U.S. pharmaceutical stocks fell before the market opened, with Novo Nordisk down 5.25%, AbbVie down 4.12%, AstraZeneca down 3.8%, Novartis down 3.7%, and Gilead Sciences down 3.46%. Trump announced that he would sign an executive order to immediately reduce drug prices by 30%-80%.
08:11
U.S. pharmaceutical stocks fell before the market opened, with Novo Nordisk (NVO.N) down 5.25%, AbbVie (ABBV.N) down 4.12%, AstraZeneca (AZN.O) down 3.8%, Novartis (NVS.N) down 3.7%, and Gilead Sciences (GILD.O) down 3.46%. Trump announced that he would sign an executive order to immediately reduce drug prices by 30%-80%.
2025.05.08
10:13
AstraZeneca's new small molecule drug plant in Wuxi officially started construction with a total investment of US$475 million
On May 8, AstraZeneca's new small molecule drug plant in Wuxi officially started construction. The new plant has a total investment of US$475 million and covers an area of about 30,000 square meters. It will be equipped with two sets of cutting-edge tablet continuous manufacturing process equipment and seven sustainable drug packaging production lines. It will mainly produce AstraZeneca's innovative cardiovascular drugs in its pipeline and is expected to be put into production in the fourth quarter of 2028. This is a further deepening of AstraZeneca's supply chain layout in China after the completion of the main building of the first phase of the Qingdao Inhalation Aerosol Production and Supply Base last month.
2025.04.30
05:00
AstraZeneca responds to latest fine in China
AstraZeneca responded to the latest fines it may face in China, saying: "The "Identification Opinion Notice" issued by the Shenzhen Customs Anti-Smuggling Bureau shows that the company is suspected of evading import taxes, amounting to more than 1.6 million US dollars." According to relevant information, AstraZeneca believes that the import taxes mentioned in the "Identification Opinion Notice" involve Enhertu. If AstraZeneca is ultimately found to be legally responsible, it may be fined one to five times the unpaid import taxes, with a maximum amount of up to 8 million US dollars.
2025.04.29
06:54
AstraZeneca (AZN.O) CEO: The impact of US tariffs on AstraZeneca will be short-lived.
2025.04.23
11:06
AstraZeneca (AZN.O) CEO: Europe is falling behind in attracting investment in pharmaceutical research and development and manufacturing.
11:04
AstraZeneca (AZN.O) CEO: Europe has increased defense spending and now must protect its medical sovereignty.
2025.04.22
07:10
AstraZeneca: Viagra approved in China for the treatment of adult patients with generalized myasthenia gravis
On April 22, AstraZeneca announced that the long-acting C5 complement inhibitor Ultomiris (English trade name: Ultomiris, generic name: reslizumab injection) was officially approved in China for use in combination with conventional treatment drugs to treat adult generalized myasthenia gravis (gMG) patients with positive anti-acetylcholine receptor (AChR) antibodies. Currently, reslizumab has been approved for the treatment of adult gMG patients with positive anti-AChR antibodies in the United States, the European Union, Japan and other countries and regions, and has been approved for multiple indications in many countries and regions around the world.
06:42
AstraZeneca's new myasthenia gravis antibody drug approved in China, to be administered once every 8 weeks
On April 22, AstraZeneca announced that the marketing application for ravulizumab injection has been approved by the China National Medical Products Administration (NMPA) for use in combination with conventional treatment drugs to treat adult generalized myasthenia gravis (gMG) patients who are positive for anti-acetylcholine receptor (AChR) antibodies. Ravulizumab is a long-acting complement C5 protein inhibitor that is administered once every 8 weeks.
04:20
AstraZeneca: Trancocort combined with Fulvestrant approved in China for patients with HR-positive advanced breast cancer
On April 22, AstraZeneca announced that the China National Medical Products Administration officially approved Capisetid (generic name: Capisetid tablets) combined with Fulvestrant on April 15, 2025 for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one endocrine therapy in the metastatic stage, or relapsed during adjuvant therapy or within 12 months after completion of adjuvant therapy, who are hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and have one or more PIK3CA/AKT1/PTEN changes.
Load More
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
Weekly Highlights
Air India flight returns after takeoff due to technical issues

2025-06-16

Southbound funds made a large net purchase of 5.743 billion yuan today. In terms of Hong Kong Stock Connect (Shanghai), China Construction Bank and Meituan-W received net purchases of HK$1.108 billion and HK$493 million respectively; Xiaomi Group-W ranked first in net sales, with an amount of HK$1.489 billion; in terms of Hong Kong Stock Connect (Shenzhen), Meituan-W and Kangfang Biopharma received net purchases of HK$622 million and HK$206 million respectively; Xiaomi Group-W ranked first in net sales, with an amount of HK$391 million.

2025-06-16

Arm (ARM.O): We are better than Nvidia on a wider range of platforms.

2025-06-12

Lei Jun: Xiaomi Yu7 will be released at the end of June

2025-06-16

Putin: Russia will create unmanned system forces as a separate branch of the military

2025-06-13

ASIA TECH WIRE

Grasp technology trends

Download